CPRIT awards MD Anderson over $29 million for prevention efforts, cancer research and faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded over $29 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of impactful prevention programs, groundbreaking cancer research efforts and faculty recruitment.
“We sincerely appreciate CPRIT for their continued support of cancer research and prevention at MD Anderson,” said Giulio Draetta, M.D., Ph.D., chief scientific officer at...
Allison Institute’s third annual scientific symposium highlighted by panel discussion with five Nobel laureates
Sessions focused on the latest advances in cancer vaccines, immunotherapy and immunology research
Symposium featured a panel discussion with...
Cancer-associated nerve injury leads to chronic inflammation and immunotherapy resistance
Study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation
These nerve injuries drive...
Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later
Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery
87% of patients remained alive and 80% were disease free four years after treatment
Nearly all patients whose tumors responded to treatment before surgery remained disease-free after four years
Researchers found potential biomarkers that can highly predict which patients have better outcomes or are at high risk of recurrence...
CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded $21.4 million from the Cancer Prevention and Research Institute of Texas...
AACR: New CAR T cell therapy benefits patients with advanced thyroid cancers
Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress...
AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life...
AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors
Drug works similarly to other DNA...
AACR: Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial
Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1...
AACR: Researchers share promising results from MD Anderson clinical trials
ABSTRACTS: CT012, CT132, CT265
Researchers from The University of Texas MD Anderson Cancer Center will present promising...
AACR: MD Anderson researchers share cancer breakthroughs
ABSTRACTS: 1186, 3746, 3763, 3776, 3824, 6367, 6384, 6396, 6424, 6427, 6436, 6438,
CHICAGO ― Researchers from The University of Texas...
AACR: MD Anderson’s John Weinstein elected Fellow of the AACR Academy
CHICAGO ― John N. Weinstein, M.D., Ph.D., chair of Bioinformatics and Computational Biology and professor of Systems Biology...
MD Anderson Research Highlights for February 26, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson receives nearly $23 million in CPRIT funding for cancer research, faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of...
Scientists find new biomarker that predicts cancer aggressiveness
Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD Anderson Cancer...
MD Anderson Research Highlights for February 10, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson Research Highlights for January 9, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...